SUNNYVALE, Calif., Aug. 21, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that physicians at the
Froedtert & the Medical College of
Wisconsin ("MCW") Clinical Cancer Center at Froedtert
Hospital in Milwaukee, Wisconsin
have treated the first cancer patient in the world, a 45-year-old
man with lung cancer, using the Radixact® System with
Synchrony® motion tracking and correction
technology1. With the addition of Synchrony, the
Radixact System was able to track the lung tumor in real-time as it
moved with the patient's breathing and automatically adjust the
radiation beam to keep it targeted on the tumor. This enabled the
clinical team to deliver the maximum dose of radiation they felt
necessary to destroy cancer cells, while minimizing the risk of
damage to surrounding healthy tissues. The Radixact and
CyberKnife® Systems are the only radiation therapy
delivery systems with this sophisticated Synchrony automated motion
tracking and correction functionality.
The Froedtert & MCW Clinical Cancer Center in Milwaukee, Wisconsin, part of the Froedtert
& MCW Cancer Network, is dedicated to using advanced treatment
options to provide personalized treatments for every cancer
patient. The clinical team installed the Synchrony upgrade because
they wanted to further enhance the ability to deliver precise
radiation treatment to their patients requiring this form of cancer
therapy.
"The Froedtert & MCW Radiation Oncology team continues to
identify and integrate technical advancements that have the
potential to make radiation therapy treatment as precise, safe and
effective as possible," said Christopher
Schultz, M.D., FACR, FASTRO, Medical
College of Wisconsin Professor and Chairman of the
Department of Radiation Oncology with the Froedtert & MCW
Cancer Network. "We have successfully treated the first patient,
diagnosed with a lung tumor, using the Radixact System with
Synchrony technology. With Synchrony, we were able to use a smaller
treatment field when delivering radiation to the tumor as it moved.
Without this technology, larger treatment fields would have been
necessary to treat the entire path of the tumor movement.
Alternatively, a much longer treatment time would have been needed
to turn the radiation beam on and off as the tumor moved in and out
of the specified treatment window. Overall, we believe that the
addition of Synchrony to our Radixact System will expand treatment
options for patients with mobile tumors, including those that are
currently too large to treat without motion tracking."
"In our hospital network we've seen an increase in the use of
hypofractionated stereotactic body radiation therapy as part of the
cancer treatment, making it critically important that we are able
to safely deliver the correct amount of dose precisely to the
tumor, even to those that move such as tumors in thorax, abdomen
and pelvis," said X. Allen Li,
Ph.D., Medical College of Wisconsin
Professor and Chief of Medical Physics at Froedtert Hospital. "Our
comprehensive pre-treatment tests and the initial patient treatment
showed us how well the Synchrony technology works in the real-world
clinical practice. As a result, we now have an option for precisely
and accurately delivering radiation to tumors as they move, which
will expand the range of tumors we can confidently treat and the
patients we can help."
Listen to the Froedtert & MCW Radiation Oncology team share
their experiences using Radixact with Synchrony at this link:
https://youtu.be/SRIbJ3_MeKs
Synchrony for the Radixact System is designed to correct for
tumors that move as a result of bodily processes, including
respiration and digestion, as well as patient movement. Synchrony
is the only technology that uses image guidance during treatment
delivery to automatically adjust the movement of the radiation beam
in synchronization with the movement of the tumor. The beams of
radiation are delivered continuously throughout the treatment
session as the patient breathes naturally. In comparison, gating
methods deliver radiation only when the tumor is close to the
expected location and pause treatment delivery when the moving
tumor is outside of the "treatment window." This potentially
lengthens the treatment time and can compromise clinical
efficacy.
Additionally, the combination of Synchrony® with the
Radixact® System facilitates the efficient and effective
delivery of both hypofractionated and standard radiation therapy,
making it easier for clinical teams to provide treatments tailored
to meet each individual patient's needs. This functionality
directly supports the key priority of value-based healthcare
delivery models, such as an Alternative Payment Model, which
economically reward treatment quality and efficiency to improve
patient outcomes. The combination of Synchrony® with the
Radixact® System is a big step forward for patients, and
clinical providers who treat them.
"We congratulate Dr. Schultz, Dr. Li and the entire Froedtert
& MCW Cancer Network team on treating the first cancer patient
using the Radixact System with Synchrony," said Birgit Fleurent, chief marketing officer at
Accuray. "This treatment demonstrates the value that Synchrony for
the Radixact System brings to the treatment of cancer and the
Accuray team's commitment to providing clinicians with the
resources they need to help them achieve their clinical objectives
for all cancer patients, even those with tumors that move."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, and the
ability of Synchrony to expand the treatment options for patients
with mobile tumors as well as the range of tumors being treated
with the Radixact® System. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products, including new product offerings and
improvements; the company's ability to develop new products or
improve existing products to meet customers' needs; the company's
limited long-term clinical data supporting the safety and efficacy
of its products, including product improvements, for certain users
and such other risks identified under the heading "Risk Factors" in
the company's quarterly report on Form 10-Q, filed with the
Securities and Exchange Commission (the "SEC") on May 9, 2019 and as updated periodically with the
company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
1 "Synchrony® Motion Tracking and
Correction Technology" is synonymous with the development name:
"Motion Tracking and Compensation Feature for the
Radixact® Treatment Delivery System"
View original content to download
multimedia:http://www.prnewswire.com/news-releases/froedtert--the-medical-college-of-wisconsin-cancer-network-is-first-in-the-world-to-treat-cancer-patient-using-the-accuray-radixact-system-with-synchrony-motion-tracking-and-correction-technology-300904807.html
SOURCE Accuray Incorporated